These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 11791957)

  • 1. Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi.
    Dietze R; Carvalho SF; Valli LC; Berman J; Brewer T; Milhous W; Sanchez J; Schuster B; Grogl M
    Am J Trop Med Hyg; 2001 Dec; 65(6):685-9. PubMed ID: 11791957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis.
    Sherwood JA; Gachihi GS; Muigai RK; Skillman DR; Mugo M; Rashid JR; Wasunna KM; Were JB; Kasili SK; Mbugua JM
    Clin Infect Dis; 1994 Dec; 19(6):1034-9. PubMed ID: 7888530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya.
    Wasunna MK; Rashid JR; Mbui J; Kirigi G; Kinoti D; Lodenyo H; Felton JM; Sabin AJ; Albert MJ; Horton J
    Am J Trop Med Hyg; 2005 Nov; 73(5):871-6. PubMed ID: 16282296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
    Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S
    J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.
    Berman JD; Badaro R; Thakur CP; Wasunna KM; Behbehani K; Davidson R; Kuzoe F; Pang L; Weerasuriya K; Bryceson AD
    Bull World Health Organ; 1998; 76(1):25-32. PubMed ID: 9615494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India.
    Jha TK; Sundar S; Thakur CP; Felton JM; Sabin AJ; Horton J
    Am J Trop Med Hyg; 2005 Dec; 73(6):1005-11. PubMed ID: 16354802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Injectable paromomycin for Visceral leishmaniasis in India.
    Sundar S; Jha TK; Thakur CP; Sinha PK; Bhattacharya SK
    N Engl J Med; 2007 Jun; 356(25):2571-81. PubMed ID: 17582067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trial of oral miltefosine for visceral leishmaniasis.
    Sundar S; Rosenkaimer F; Makharia MK; Goyal AK; Mandal AK; Voss A; Hilgard P; Murray HW
    Lancet; 1998 Dec; 352(9143):1821-3. PubMed ID: 9851383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Para-kala-azar dermal leishmaniasis in a patient in Brazil: a case report.
    Lindoso JAL; Moreira CHV; Celeste BJ; Oyafuso LKM; Folegatti PM; Zijlstra EE
    Rev Soc Bras Med Trop; 2018; 51(1):105-107. PubMed ID: 29513829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of visceral leishmaniasis with amphotericin B colloidal dispersion.
    Berman J; Dietze R
    Chemotherapy; 1999 Jun; 45 Suppl 1():54-66. PubMed ID: 10394022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Brazilian kala-azar with a short course of amphocil (amphotericin B cholesterol dispersion).
    Dietze R; Milan EP; Berman JD; Grogl M; Falqueto A; Feitosa TF; Luz KG; Suassuna FA; Marinho LA; Ksionski G
    Clin Infect Dis; 1993 Dec; 17(6):981-6. PubMed ID: 8110956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. To evaluate efficacy and safety of amphotericin B in two different doses in the treatment of post kala-azar dermal leishmaniasis (PKDL).
    Rabi Das VN; Siddiqui NA; Pal B; Lal CS; Verma N; Kumar A; Verma RB; Kumar D; Das P; Pandey K
    PLoS One; 2017; 12(3):e0174497. PubMed ID: 28355259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.
    Singh RP; Picado A; Alam S; Hasker E; Singh SP; Ostyn B; Chappuis F; Sundar S; Boelaert M
    Trop Med Int Health; 2012 Nov; 17(11):1345-8. PubMed ID: 22882665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
    Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D
    Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
    Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
    Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compassionate use of sitamaquine in an HIV-positive patient with visceral leishmaniasis.
    Rashid JR; Nyakundi PM; Kirigi G; Kinoti D; Wasunna MK
    Trans R Soc Trop Med Hyg; 2002; 96(5):533-4. PubMed ID: 12474482
    [No Abstract]   [Full Text] [Related]  

  • 17. Ambisome plus miltefosine for Indian patients with kala-azar.
    Sundar S; Sinha PK; Verma DK; Kumar N; Alam S; Pandey K; Kumari P; Ravidas V; Chakravarty J; Verma N; Berman J; Ghalib H; Arana B
    Trans R Soc Trop Med Hyg; 2011 Feb; 105(2):115-7. PubMed ID: 21129762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial.
    Sundar S; Agrawal G; Rai M; Makharia MK; Murray HW
    BMJ; 2001 Aug; 323(7310):419-22. PubMed ID: 11520836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cumulative cardiac toxicity of sodium stibogluconate and amphotericin B in treatment of kala-azar.
    Maheshwari A; Seth A; Kaur S; Aneja S; Rath B; Basu S; Patel R; Dutta AK
    Pediatr Infect Dis J; 2011 Feb; 30(2):180-1. PubMed ID: 20823781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial.
    Wasunna M; Njenga S; Balasegaram M; Alexander N; Omollo R; Edwards T; Dorlo TP; Musa B; Ali MH; Elamin MY; Kirigi G; Juma R; Kip AE; Schoone GJ; Hailu A; Olobo J; Ellis S; Kimutai R; Wells S; Khalil EA; Strub Wourgaft N; Alves F; Musa A
    PLoS Negl Trop Dis; 2016 Sep; 10(9):e0004880. PubMed ID: 27627654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.